Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mink Therapeutics Inc (NQ: INKT )

0.9451 -0.0249 (-2.57%)
Streaming Delayed Price Updated: 11:27 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mink Therapeutics Inc

< Previous 1 2 3 Next >
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
From MiNK Therapeutics
Via GlobeNewswire
Earnings Outlook For MiNK Therapeutics
Via Benzinga
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
MiNK Reports Fourth Quarter and Year-End 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model 
From MiNK Therapeutics
Via GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
Treatment with agenT-797 Showed Improved Survival in Severe Respiratory Distress 
From MiNK Therapeutics
Via GlobeNewswire
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
From MiNK Therapeutics
Via GlobeNewswire
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
Sacks Parente Golf And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by more than 300 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.